QSI vs. TXG, TRNS, EYPT, ALNT, LAB, CTKB, AEHR, QTRX, SENS, and MASS
Should you be buying Quantum-Si stock or one of its competitors? The main competitors of Quantum-Si include 10x Genomics (TXG), Transcat (TRNS), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Standard BioTools (LAB), Cytek Biosciences (CTKB), Aehr Test Systems (AEHR), Quanterix (QTRX), Senseonics (SENS), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
Quantum-Si vs. Its Competitors
Quantum-Si (NASDAQ:QSI) and 10x Genomics (NASDAQ:TXG) are both small-cap measuring and control equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.
Quantum-Si has a beta of 2.89, suggesting that its stock price is 189% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.
Quantum-Si has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.
39.9% of Quantum-Si shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 23.0% of Quantum-Si shares are owned by company insiders. Comparatively, 10.0% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Quantum-Si had 5 more articles in the media than 10x Genomics. MarketBeat recorded 9 mentions for Quantum-Si and 4 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 1.57 beat Quantum-Si's score of 0.13 indicating that 10x Genomics is being referred to more favorably in the news media.
Quantum-Si presently has a consensus price target of $3.48, suggesting a potential upside of 89.89%. 10x Genomics has a consensus price target of $14.96, suggesting a potential upside of 25.52%. Given Quantum-Si's stronger consensus rating and higher probable upside, research analysts clearly believe Quantum-Si is more favorable than 10x Genomics.
10x Genomics has a net margin of -25.14% compared to Quantum-Si's net margin of -2,925.41%. 10x Genomics' return on equity of -23.22% beat Quantum-Si's return on equity.
Summary
Quantum-Si beats 10x Genomics on 9 of the 16 factors compared between the two stocks.
Get Quantum-Si News Delivered to You Automatically
Sign up to receive the latest news and ratings for QSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding QSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quantum-Si Competitors List
Related Companies and Tools
This page (NASDAQ:QSI) was last updated on 7/8/2025 by MarketBeat.com Staff
